AAC Accepted Manuscript Posted Online 27 July 2015 Antimicrob. Agents Chemother. doi:10.1128/AAC.01245-15 Copyright © 2015, American Society for Microbiology. All Rights Reserved.

1	Antimicrobial peptide novicidin synergises with rifampicin, ceftriaxone and ceftazidime against
2	antibiotic-resistant Enterobacteriaceae in vitro
3	
4	Odel Soren ^{a*} , Karoline Sidelmann Brinch ^b , Dipesh Patel ^a , Yingjun Liu ^a , Alexander Liu ^c , Anthony
4	
5	Coates ^a and Yanmin Hu ^a #
6	
7	Institute for Infection and Immunity, St George's, University of London, London, United Kingdom ^a .
8	Novozymes A/S, Bagsvaerd, Denmark ^b . John Radcliffe Hospital, University of Oxford, Oxford,
9	United Kingdom ^e .
10	
11	#Address correspondence to Yanmin Hu, <u>ymhu@sgul.ac.uk</u>
12	*Present address: Centre for Biological Sciences, University of Southampton, United Kingdom.
13	
14	Running title: Novicidin Enhancement
15	Key words: Enterobacteriaceae, novicidin, antibiotic combination, rifampicin, ceftriaxone,
16	ceftazidime
17	ABSTRACT
18	The spread of antibiotic resistance amongst Gram-negative bacteria is a serious clinical threat and
19	infections with these organisms are a leading cause of mortality worldwide. Traditional novel drug
20	development inevitably leads to the emergence of new resistant strains, rendering the new drugs
21	ineffective. Therefore, reviving the therapeutic potentials of existing antibiotics represents an
22	attractive novel strategy. Novicidin, a novel cationic antimicrobial peptide, is effective against Gram-
23	negative bacteria. Here, we investigated novicidin as a possible antibiotic enhancer. The actions of
24	novicidin in combination with rifampicin, ceftriaxone and ceftazidime were investigated against 94
	1

25 antibiotic resistant clinical Gram-negative isolates and 7 strains expressing New Delhi metallo-βlactamase-1 (NDM-1). Using the chequerboard method, novicidin combined with rifampicin showed 26 synergy with over 70% of the strains, reducing the minimum inhibitory concentrations (MIC) 27 significantly. The combination of novicidin with ceftriaxone and ceftazidime was synergistic against 28 89.7% of ceftriaxone-resistant strains and 94.1% of ceftazidime-resistant strains. Synergistic 29 30 interactions were confirmed using time kill studies with multiple strains. Furthermore, novicidin increased the post-antibiotic effect (PAE) when combined with rifampicin or ceftriaxone. Membrane 31 depolarisation assays revealed that novicidin alters the cytoplasmic membrane potential of Gram-32 negative bacteria. In vitro toxicology tests showed novicidin to have low haemolytic activity and no 33 detrimental effect on cell cultures. We demonstrated that novicidin strongly rejuvenates the 34 35 therapeutic potencies of ceftriaxone or ceftazidime against resistant Gram-negative bacteria in vitro. In addition, novicidin boosted the activity of rifampicin. This strategy can have major clinical 36 implications in our fight against antibiotic resistant bacterial infections. 37

38 INTRODUCTION

Bacterial infections remain one of the leading causes of death worldwide. The ever escalating problem of antibiotic resistance leads to the redundancy of many antibiotics, resulting in increased morbidity and mortality in both developed and developing countries. In particular, the effectiveness of antimicrobial agents against Gram-negative pathogens, for example *Enterobacteriaceae*, are being compromised at an alarming rate (1).

Bacteria in the *Enterobacteriaceae* family cause an arsenal of serious infections including pneumonia, wound infections, meningitis, urinary tract infections, intra-abdominal infections (1) and nosocomial bacteriema (2). Extended spectrum β-lactamase (ESBL) producing strains now predominate in many areas, conferring resistance to cephalosporins and remaining sensitive only to carbapenems and the older, more toxic polymyxin antibiotics such as colistin (3). Furthermore, since 2007, infections with

49 New Dehli metallo-*β*-lactamase 1 (NDM-1) producing 'superbugs' have emerged. For these infections virtually all antibiotics, including carbapenems, are ineffective. Most NDM-1 strains are usually 50 susceptible only to 'last line' drugs like colistin, which exhibits nepro- and neuro-toxicity (4), and the 51 52 bacteriostatic glycylcycline tigecycline (5). The most optimal strategy to overcome resistant infections is to use novel antimicrobial agents. However, the traditional strategy of antibiotic discovery cannot 53 54 maintain pace with the rapid rate of resistance emergence and resistance occurs just a few years after market release (6). In addition, the discovery of novel antibiotics is costly and arduous which means 55 producing large numbers of antibiotic classes within a short period of time is extremely challenging 56 (7-9). 57

Reviving the potency of existing antibiotics by combining them with novel agents is an extremely 58 59 desirable strategy to tackle resistance (10). Antimicrobial peptides, in particular those targeting the 60 bacterial cell envelope, have been shown to synergise with conventional antibiotics (11). The dual 61 action of weakening of the cell envelope and increasing permeability may allow the intracellular antibiotic concentration to reach a lethal dose, which is unachievable by the antibiotic alone. 62 63 Furthermore, the use of multiple agents in combination may reduce or retard the emergence of resistance to the individual antimicrobial components (10, 12). 64

It has been suggested that novicidin, a novel 18-residue cationic antimicrobial peptide, acts by 65 66 inserting itself into the head group region of the selectively targeted bacterial membrane bilayer. This subsequently causes membrane perturbation, transient pore formation, and is bactericidal via the 67 resulting leakage of bacterial cell contents (13-15). Significant antimicrobial effects have been noted 68 with several Gram-negative organisms, such as Escherichia coli and Salmonella enterica (15). 69 Novicidin was developed from ovispirin, which in turn originated from an ovine cathelicidin known 70 71 as sheep myeloid antimicrobial peptide (SMAP)-29 (13). This derivement allowed for construction of a peptide more suitable for use as a therapeutic agent (14). 72

In this study, we aimed to investigate the effects of novicidin in combination with conventional antibiotics, namely rifampicin and third generation cephalosporins, ceftriaxone and ceftazidime, against 101 Gram-negative strains including resistant *E. coli* and bacteria in the *Klebsiella-Enterobacter-Serratia* (KES) group. Additionally, investigations were carried out to determine the mechanism of action, haemolytic activity and cytotoxicity of novicidin.

78 MATERIALS AND METHODS

79 Bacterial strains and growth conditions. Bacterial strains used were 94 antibiotic resistant Gramnegative clinical isolates including 61 E. coli and 33 isolates in the KES group from St Georges 80 Hospital, London. In addition, 7 strains harbouring the bla_{NDM} plasmid were used: ATCC BAA-2468, 81 BAA-2469, BAA-2470, BAA-2471, BAA-2472 and BAA-2473 and NCTC 13443. Strain ATCC 82 BAA-2468 is identified as Enterobacter cloacae; ATCC BAA-2469 and BAA-2471 as E. coli; and 83 ATCC BAA-2470, BAA-2472, BAA-2473 and NCTC 13443 as Klebsiella pneumoniae. Bacterial 84 85 strains were grown in nutrient broth no. 2 (Oxoid, UK) and on tryptone soya agar plates (Oxoid, UK). 86 Antibiotics used were as follows: rifampicin (Sanofi), ceftriaxone (Stravencon), ceftazidime 87 (Wockhardt), cefixime (Suprax) and cefotaxime (Reig Jofre). Antibiotics were prepared in water or the provided solvent to an appropriate concentration. Novicidin was kindly provided by Novozymes 88 A/S, Denmark. 89

In vitro susceptibility of novicidin and antibiotics. The minimum inhibitory concentration (MIC) of novicidin, rifampicin, ceftriaxone, ceftazidime, cefixime and cefotaxime for the 101 strains were calculated using the broth micro dilution method. The MIC for each agent was identified as the lowest concentration required to inhibit bacterial growth. The MIC50 and MIC90 were calculated, defined as the lowest concentration required to inhibit growth in 50% and 90% of the strains respectively.

95 Chequerboard assays to measure combination effects of novicidin and antibiotics. The 96 chequerboard assay method was used for the measurement of combination effects of novicidin with

97 the antibiotics. Combinations of two drugs were prepared in 96 well plates (Fisher Scientific UK) using drug concentrations starting from two fold higher than their MIC values, then serially diluted in 98 a two-fold manner. After addition of a log-phase bacterial inoculum of $1-5 \times 10^5$ colony forming units 99 (CFU)/ml, plates were incubated at 37°C for 24 hours. and then read using ELx800 absorbance 100 microplate reader (BioTek). The effects of the combinations were examined by calculating the 101 102 fractional inhibitory concentration index (FICI) of each combination as follows: (MIC of drug A, tested in combination)/(MIC of drug A, tested alone) + (MIC of drug B, tested in combination)/(MIC 103 of drug B, tested alone). The profile of the combination was defined as synergistic if the FICI was 104 ≤ 0.5 , indifferent if the FICI was > 0.5 but ≤ 4.0 and antagonistic if the FICI was > 4 (16). 105

Time kill curves of antibiotics alone and in combination with novicidin. Two-fold serial drug 106 107 dilutions were prepared and added to a 96-well plate alone and in combination, and incubated at 37°C with a log-phase bacterial inoculum of $1-5 \times 10^7$ CFU/ml. At 0, 1, 2, 4, 7 and 24 hours of incubation, 108 viability expressed as CFU/ml was determined by plating 100 µl of serial dilutions onto tryptone soya 109 agar (Oxoid) plates followed by incubation at 37°C for 24 hours. Colonies were counted using 110 111 aCOLyte colony counter (Synbiosis) and analysed using the accompanying software. Synergistic activity was defined as a \geq 2-log₁₀ decrease in CFU counts at 24 hours of the combination compared 112 with the most effective single agent, in addition to $\geq 2 - \log_{10}$ decrease compared with the 0 hour count. 113 Indifference was defined as a $\leq 1 - \log_{10}$ fold change in CFU counts, and antagonism as a $\geq 2 - \log_{10}$ 114 increase in CFU at 24 hours, of the combination compared with the most effective single agent (17). 115

116 **Measurement of bacterial cytoplasmic membrane potential**. The permeability of the bacterial 117 cytoplasmic membrane after drug treatment was assessed using a fluorescence assay as previously 118 described (18, 19). Log-phase cultures were washed twice and resuspended in a rejuvenating buffer 119 (5 mM HEPES, pH 7.2, 20mM glucose) to an optical density of 0.05 at 600 nm. Membrane potential 120 sensitive dye DiSC3(5) (3'3-Dipropylthiadicarbocyanine iodide, Sigma) was added to the resuspended 121 cells to a final concentration of 0.4 μ M and incubated until a stable reduction in fluorescence was

Chemotherapy

achieved as a result of DiSC3(5) uptake and cell quenching due to an intact membrane. 100 mM of
KCl was added to equilibrate the K+ ion concentration intra- and extracellularly. The bacterial cell
suspension was added to a 96-well microtitre plate, followed by addition of drugs in triplicate.
Fluorescence was measured using GloMax-Multi+ microplate reader (Promega) at an excitation
wavelength of 622 nm and an emission wavelength of 670 nm. Any drug induced disruption of the
cytoplasmic membrane resulted in an increase in measurable florescence.

Post-Antibiotic Effect (PAE) of antibiotics alone and in combination with novicidin. Bacteria 128 were cultured overnight at 37°C in nutrient broth. 1 ml of the culture was transferred to fresh nutrient 129 broth medium containing single or combinatory drugs. For the single drugs, 2, 5 or 10 fold higher than 130 131 MIC values of the drug were utilised. For the combinations, 5 fold higher than the minimal 132 enhancement concentrations of both drugs were selected according to the chequerboard results. After 133 1 hour of drug exposure, the cultures were washed three times to remove the antimicrobial agents. The 134 bacterial cells were resuspended into nutrient broth and grown at 37°C with continuous shaking at 100 rpm. Bacterial viability was determined by CFU counting at 0, 1, 2, 3, 4, 6 and 8 hours. The PAE 135 136 was calculated as follows: PAE = T - C, whereby T= time taken for drug exposed culture to increase by 1 log CFU counts, and C = time taken for control culture to increase by 1 log CFU counts (20). 137

Ex vivo haemolysis assay. A venous blood sample from a male human donor was collected shortly 138 139 before testing. 10 µl aliquots of the heparinized blood were added to 0.5 ml of saline solution (0.9% NaCl) containing different concentrations of novicidin in triplicate. After 1 hour of incubation at 140 37°C, the mixtures were centrifuged for 5 minutes at 5000 \times g to sediment intact cells. The 141 supernatants were isolated and the absorbance values were measured at a wavelength of 545 nm. 142 Haemolysis of novicidin was analysed against negative (0% lysis) and positive controls (100% lysis) 143 to calculate the percentage of haemolysed cells, using the formulae as follows: haemolysis = $(OD_{test} - CD_{test})$ 144 OD_{negative control}) / (OD_{postitive control} - OD_{negative control}) x 100. An ethic approval (H-D-2007-0055) was 145 obtained from Danish National Committee on Health Research Ethics for using human blood. 146

147 Assessment of cytotoxicity using neutral-red uptake assay. To assess the effects of cytotoxicity of novicidin, the L929 mouse fibroblast cell line was utilised. Cells were grown in Eagle's minimum 148 essential medium (EMEM) with 10% foetal bovine serum (EBS) to 80% confluence. Adherent cells 149 were harvested and seeded at a concentration 5×10^5 cells per well into a 96 well microtitre plate 150 which was incubated for 24 hours at 37°C. Different concentrations of novicidin were added to the 151 152 cells and incubated at 37°C for 24 and 72 hours. Neutral red (25 mg/L) was added post treatment for 3 hours at 37°C and removed by washing the cells twice with phosphate buffered saline containing 153 CaCl₂/MgCl₂. Intracellular neutral red was extracted using neutral red removal solution (50% ethanol, 154 155 1% acetic acid and 49% water) for 15 minutes. Neutral red uptake was measured at 540 nm and cell viability was determined as percentage of the untreated control. Sodium dodecyl sulphate (SDS) was 156 157 used as a positive control.

158 RESULTS

159 In vitro susceptibility of novicidin and the antibiotics. The MIC for novicidin, rifampicin, 160 ceftriaxone, ceftazidime, cefixime and cefotaxime were assessed for the 94 Gram-negative clinical 161 isolates and 7 NDM-1 strains. As shown in Table 1, the MIC for novicidin for the 101 strains ranged from 1 to 8 mg/L with an MIC50 and MIC90 at 2 and 4 mg/L, respectively. The MIC for rifampicin 162 varied between 4 to >1024 mg/L. The MIC50 and MIC90 were 16 mg/L and 64 mg/L, respectively. 163 164 The MIC for ceftriaxone, ceftazidime, cefixime and cefotaxime ranged between 0.03125 and 2048 mg/L. The MIC50 and MIC90 were 1024 and 2048 mg/L for ceftriaxone, 128 and 1024 mg/L for 165 ceftazidime, 256 and 2048 mg/L for cefixime, and 512 and 2048 mg/L for cefotaxime, respectively. 166

167 Chequerboard analysis of combination effects. The combination effects of novicidin combined with rifampicin, ceftriaxone and ceftazidime were determined using the broth microdilution 168 chequerboard assay against 94 clinical isolates and 7 NDM-1 strains. The FIC indices for the 169 combinations are shown in Table 2. The combination of novicidin with rifampicin was shown to have 170

Chemotherapy

171

between 0.018 and 0.5. In addition, the combination was shown to have synergistic effects with all 7 172 NDM-1 strains. Novicidin reduced the MIC of rifampicin between 2 to 512-fold, with the majority of 173 strains exhibiting 4 or 8-fold reductions in MIC values (Supplementary Table 1, 2 and 3). Novicidin 174 combined with ceftriaxone showed synergy with 57.4% of the E. coli strains and 69.7% of isolates in 175 176 KES group. The combination of novicidin with ceftazidime presented synergy with 63.9% of the E. coli strains and 78.8% of isolates in KES group. The FIC indices for the NDM-1 strains were unable 177 to be determined as the MIC for ceftriaxone and ceftazidime was higher than the maximum achievable 178 chequerboard concentration of 2048 mg/L. As revealed in Table 3, synergistic activities were shown 179 in the majority (89.7%) of the ceftriaxone-resistant strains compared to a minority of the ceftriaxone-180 181 sensitive strains (16.7%). A similar pattern was observed with the novicidin and ceftazidime combination, whereby synergy was seen in 94.1% of resistant strains compared with 3.8% of sensitive 182 183 strains. Novicidin reduced the MIC of ceftriaxone or ceftazidime between 2 to more than 2048-fold (Supplementary Table 1 and 2). 184

synergistic activity with over 70% of both E. coli and isolates in KES group, with FIC indices

185 Time kill assays confirming synergy of novicidin combined with rifampicin, ceftriaxone or 186 ceftazidime. Time kill assays were performed to examine the activities of novicidin in combination with rifampicin, ceftriaxone and ceftazidime against 5 strains of E. coli and KES group clinical strains 187 which represented an FIC index <0.5 for each drug combination. The combination of rifampicin and 188 189 novicidin was also tested against the 7 NDM-1 strains. A range of different concentrations was tested according to chequerboard analysis and the most effective and synergistic activities are shown. As 190 191 seen in Figure 1, rifampicin at 2 mg/L (Fig. 1A and Fig. 1B) and at 256 mg/L (Fig. 1C and 1D) failed to reduce the viability of the clinical isolate and the NDM-1 E. coli, novicidin at 0.5 or 0.25 mg/L 192 193 (Fig. 1A and 1B) and at 4 or 2 mg/L (Fig. 1C and 1D) showed initial kill of the bacteria but regrowth was seen. However, when rifampicin at 2 mg/L combined with novicidin at 0.5 (Fig. 1A) or 0.25 (Fig. 194 1B) mg/L, 100% kill of the *E. coli* cells was achieved at 2 and 4 hours post treatment, respectively. 195

Similarly, when rifampicin at 256 mg/L combined with novicidin at 4 (Fig. 1C) or 2 (Fig. 1D) mg/L, complete kill of the NDM-1 *E. coli* was seen at 4, 7 and 24 hours post treatment, respectively. There were significant differences in the reduction of CFU counts between the combination of novicidin with rifampicin and each of the single drug (rifampicin or novicidin) treatment (P<0.0001).</p>

200 Novicidin and ceftriaxone combinations were tested against ceftriaxone resistant E. coli and KES group clinical isolates. As seen in Fig. 1E, 1F, 1G and 1H, ceftriaxone at 2048 mg/L was unable to 201 reduce the CFU counts of both strains. However, when novicidin was added in the culture at 1 or 0.5 202 mg/L and 2 or 1 mg/L, the bacterial cells were rapidly killed showing 100% reduction in CFU count at 203 204 2 or 4 hours post treatment for the E. coli isolate respectively (Fig. 1E and 1F), and at 1 or 2 hours post treatment for the KES group strain (Fig. 1G and 1H) respectively, demonstrating significant 205 206 synergy. There were significant differences in the reduction of CFU counts between combination of 207 novicidin with ceftriaxone and each of the single drug (ceftriaxone or novicidin) treatment 208 (P<0.0001). The ability of novicidin enhancement to rifampicin or ceftriaxone was also compared 209 with another defensin, plectasin which was neither bactericidal on its own nor boosting the activity of 210 rifampicin (Fig. 11) or ceftriaxone (Fig. 1J) against Gram-negative bacteria to validate the assay. 211 Similar patterns of combination activities were observed for the strains tested when novicidin was 212 combined with ceftazidime (data not shown).

213 Membrane permeabilising effects of novicidin against E. coli and KES group isolates. The effects of novicidin at the cytoplasmic bacterial membrane with both E. coli and an isolate from the KES 214 215 group were investigated with fluorescence assays. Immediately after novicidin exposure, a sharp concentration dependent increase in fluorescence occurs with the E. coli strain (Fig. 2) indicating 216 217 disruption of the bacterial membrane which led to the leakage of the fluorescent dye. A similar effect 218 was observed when novicidin was used to treat the strain in the KES group despite only high concentrations of novicidin such as 64 and 32 mg/L resulting in an increase in fluorescence (data not 219 220 shown).

Accepted Manuscript Posted Online

Antimicrobial Agents and

Antimicrobial Agents and

221 Post-antibiotic effect of novicidin and novicidin-antibiotic combinations. The PAE of novicidin, rifampicin or ceftriaxone singly and in combination was determined; rifampicin was used at 5-fold 222 higher than the MIC level and ceftriaxone at 10-fold higher than the MIC level. As novicidin was 223 rapidly bactericidal at 5-fold higher than its MIC concentration, 2-fold higher than MIC level was 224 used to induce the PAE. Due to their enhanced synergistic activities, the same concentrations for 225 226 novicidin and rifampicin or ceftriaxone used singly for PAE induction would completely kill all the bacterial cells within 1 hour if combined. Therefore, to induce PAE with combination treatment, 5-227 fold higher than the minimal enhancement concentrations for novicidin and rifampicin or ceftriazone 228 were used, chosen from chequerboard results. As shown in Fig. 3A, the PAE of both novicidin and 229 rifampicin was estimated as 52.8 minutes for the E. coli strain. The novicidin and rifampicin 230 231 combination doubled the PAE to 121.8 minutes despite substantially lower concentrations being used (P<0.0001). As shown in Fig. 3B, the PAE of novicidin was 84 minutes and ceftriaxone produced no 232 PAE. The novicidin and ceftriaxone combination exhibited a prolonged PAE of 117 minutes 233 (P<0.0001). 234

235 Haemolytic effects of novicidin. Haemolysis of novicidin was tested using human blood. As shown 236 in Table 4, at the lowest tested novicidin concentration of 125 mg/L, haemolysis occurred at a rate of 4.4% ranging up to 19.9% at the highest tested concentration of 1000 mg/L. The 50% haemolytic 237 concentration could not be accurately predicated due to the non-linear correlation between novicidin 238 239 concentration and haemolysis, however is shown to be >1000 mg/L from the current data. Extrapolation provides an estimate of between 2500 and 3000 mg/L. 100% haemolysis was seen 240 when the blood was added into distilled water (Table 4). The experiments were repeated twice with 241 242 reproducible results.

Determination of cytotoxicity by neutral-red uptake. To assess the cytotoxicity of novicidin, 243 neutral-red uptake was measured after treatment of the murine fibroblasts with different 244 concentrations of novicidin. As seen in Table 5, cell viability was well conserved and remained 245

between 93% to 99% after 24 hours of novicidin exposure, and 98% to 102% after 72 hours exposure for all tested concentrations. This indicates low levels of general cytotoxicity even with prolonged exposure. SDS was used as a positive control: concentrations of 80, 100 and 120 mg/L reduced cell viability to 80%, 9% and 0% at 24 hours and 55%, 0% and 0% at 72 hours, respectively, confirming the validity of the assay. The experiments were repeated twice with reproducible results.

251 DISCUSSION

Novicidin is a newly derived antimicrobial peptide. In this study, we demonstrated for the first time that novicidin synergised with rifampicin and third generation cephalosporins (ceftriaxone and ceftazidime) against Gram-negative antibiotic-resistant bacterial strains *in vitro*. The 94 clinical isolates from the *Enterobacteriaceae* family covered a broad host distribution in the South London area and the 7 NDM-1 strains represented the most resistant type of Gram-negative bacteria. Most of the ceftriaxone and ceftazidime resistant bacteria were also resistant to cefotaxime and cefixime indicating these were ESBL producing strains.

Rifampicin is an important component of the combination regimen used for the treatment of 259 260 tuberculosis and many Gram-positive bacterial infections (21). Rifampicin is not considered to be 261 standard treatment for Enterobacteriaceae infections, and thus a breakpoint for resistance is not 262 available. Our results showed that the MIC50 and MIC90 for rifampicin were 16 and 32 mg/L, respectively. Recently, rifampicin has been introduced in combination therapy for the treatment of 263 infections caused by multi-drug resistant Gram-negative bacteria (22, 23). Our chequerboard analysis 264 reveals that the combination of novicidin and rifampicin showed synergistic effects with over 70% of 265 266 the tested strains with marginally higher effectiveness with the bacterial strains in KES group compared with E. coli. Novicidin was able to revive the activity of rifampicin by reduction of 267 rifampicin MIC between 2 to 512 fold. The combination was also synergistic with all of the strains 268 harbouring NDM-1 plasmids. Synergistic activity of novicidin with rifampicin was confirmed using 269

270

time kill assays, a method allowing for a more dynamic analysis of bactericidal and combinatorial

effects. Time kill assays were performed with multiple strains, repeatedly demonstrating that at 271 concentrations at which both novicidin and rifampicin were ineffective alone, when combined, rapid 272 bactericidal activities were seen with 100% elimination of the bacterial cells within a few hours of 273 drug exposure, which substantially speeded up the treatment duration. Rifampicin alone required 274 275 higher concentrations such as 128 mg/L to completely eradicate E. coli cells in culture (data not shown) and this concentration was only able to reduce the CFU counts of a KES group strain by 2 276 logs (data not shown). However when combined with novicidin at 0.5 or 1 mg/L, rifampicin at 277 concentrations of just 2 mg/L killed 100% of the bacterial cells at 4 or 2 hours post treatment (Fig. 1A 278 and 1B). The combination was also able to enhance the activities of rifampicin against the NDM-1 279 280 strains (Fig. 1C and 1D), however required high rifampicin concentrations.

281 Novicidin also enhanced the activities of ceftriaxone and ceftazidime. Interestingly, the majority of 282 synergy was observed with those strains showing resistance to ceftriaxone or ceftazidime. This was also confirmed with time kill assays tested against multiple strains. Ceftriaxone has a long half-life 283 284 and is used to treat septicaemia, pneumonia, meningitis and urinary tract infections. Clinical 285 pharmacokinetic data revealed that after a single intravenous injection of a standard 2000 mg dose, the plasma Cmax was approximately 257 mg/L and at 24 hours post administration, the plasma 286 concentration was approximately 15 mg/L. However, in the urine, the Cmax of ceftriaxone was 287 288 approximately 2692 mg/L within 2 hours following 2000 mg intravenously administrated (24). Ceftazidime, like ceftriaxone, has broad spectrum activity and is one of the few agents in this class to 289 290 be used clinically against *Pseudomonas* spp. Ceftazidime pharmacokinetic data shows comparative serum Cmax, as a 1000 mg intravenous dose produced a peak concentration of approximately 140 291 292 mg/L. Similarly, much higher concentrations are present in the urine. Up to 6 hours post infusion of a 293 50 mg/kg dose of ceftazidime, the concentration in collected urine samples ranged from 2370 to 11, 340 mg/L, with approximately 75% of the drug being recovered unchanged (25). Based on this data, it 294

Antimicrobial Agents and

Chemotherapy

may be argued that novicidin-cephalosporin combinations may not be clinically appropriate for the treatment of septicaemia as 2048 mg/L appears to be an unattainable serum concentration. However, pharmacokinetic analysis of novicidin in combination with the antibiotics may give more realistic estimations of the concentrations required to achieve synergistic and bactericidal effect. Nevertheless, the extremely high concentrations of both ceftriaxone and ceftazidime in the urine indicate that either of these in combination with novicidin may be clinically applicable in treating urinary tract infections.

> The combination of novicidin with rifampicin or ceftriaxone was able to suppress bacterial growth 301 302 against our tested bacterial strains after the drugs had been removed. Interestingly, although 303 ceftriaxone alone was unable to produce a PAE (26), a prolonged PAE was generated in the combination with novicidin. Therefore, novicidin and the antibiotic combinations, possibly by 304 305 prolonging the PAE, are able to reduce the likelihood of resistance development. A longer PAE also 306 contributes a therapeutic advantage in devising dosing intervals for drug regimens. Generally a longer 307 PAE enables less frequent drug doses whilst maintaining therapeutic efficacy; this can reduce adverse effects and increase patient compliance (20). 308

> 309 The precise mechanism underlying the antibiotic enhancing activities of novicidin is unclear. Due to 310 decreased cell envelope permeability and altered efflux-pump systems, Gram-negative bacteria are intrinsically resistant to many antibiotics, such as rifampicin. Rifampicin inhibits bacterial DNA-311 dependant RNA polymerase (23) and its action on bacterial cells is concentration dependent. It has 312 313 been shown that compounds which target the cell wall or cell membrane were found to potentiate the activities of other antibiotics (11, 18, 27, 28). Previous work on artificial membranes showed that low 314 315 concentrations of novicidin resulted in transient pore formation and increased concentrations cause cell membrane disruption (13, 29). It is also suggested that novicidin accumulates on the membrane 316 surface until a detergent-like disintegration occurred (known as the carpet mechanism) (13). 317 318 Consistent with this finding, we showed that novicidin disturbed the cytoplasmic membrane potential by depolarising the membrane, and even at very low concentrations, significant fluorescence release 319

AAC

was observed. It is likely that the enhanced activities of rifampicin by novicidin was due to increased
cell membrane permeability against the Gram-negative bacteria leading to higher intracellular
accumulation of rifampicin (30, 31).

323 Cephalosporins are β -lactam antibiotics and interact with transpeptidases also known as penicillin binding proteins (PBP) (32), blocking the terminal step in bacterial cell wall biosynthesis (33). 324 Accordingly, the synergy between novicidin and ceftriaxone or ceftazidime may be attributed to a 325 'double hit' mechanism: (1) the disruption of the membrane by novicidin, and (2) the inhibition of cell 326 well biosynthesis by ceftriaxone or ceftazidime, which may be sufficient in reducing the integrity of 327 328 the cell envelope, resulting in cell death. Our chequerboard analysis showed that synergy was more likely with ceftriaxone or ceftazidime resistant strains, and resistance to such agents is usually due to 329 330 the acquisition of plasmids carrying ESBL genes, producing enzymes which hydrolyse the β -lactam 331 ring of antibiotics. It is unclear how novicidin enhances the activities of these cephalosporins against 332 resistant strains. We hypothesized that the enhanced antibiotic activities was likely due to the action of pore formation by novicidin, leading to the elimination of enzymes or plasmids, the resistance 333 334 determinants. However, this notion needs to be further tested.

335 The findings from our study demonstrate proof of concept, displaying the potential of peptideantibiotic combinations which undoubtedly contribute to important clinical applications. Firstly, our 336 337 demonstration of novicidin as a powerful antibiotic enhancer strongly illustrates that other similar peptides or compounds may potentially be beneficial above and beyond their direct anti-microbial 338 properties. Secondly, addition of novicidin reduced MICs and improved the rate of bactericidal 339 activities of antibiotics, therefore highly resistant Gram-negative bacteria which are extremely 340 341 difficult to kill can be eliminated from the bacterial culture. Finally, novicidin exhibited a very low haemolytic activity which was in agreement with those found by Dorosz et al (14). In addition, 342 novicidin was non-toxic and cell viability was well conserved after treatment with different 343 concentrations of novicidin. Combination therapy with novicidin shows promise for becoming a novel 344

Chemotherapy

345 and much clinically desired therapeutic option to treat "superbug" infections. In vivo work is under

346 way aiming to expose the therapeutic potential of novicidin in the combination regimen to treat

347 infections caused by antibiotic resistant Gram-negative bacteria.

348 ACKNOWLEDGMENTS

- 349 This work was funded with support from the European Commission under grant agreement no:
- 350 278998, BacAttack. This communication reflects the views only of the author, and the Commission
- 351 cannot be held responsible for any use which may be made of the information contained therein.
- 352 We would like to thank Dr Julie Johnson from St George's Healthcare NHS Trust for kindly
- 353 providing the clinical strains and Novozymes A/S Denmark for providing novicidin.

354 REFERENCES

- Paterson DL. 2006. Resistance in gram-negative bacteria: *Enterobacteriaceae*. Am J Infect Control
 34:S20-28; discussion S64-73.
- Kang CI, Kim SH, Park WB, Lee KD, Kim HB, Kim EC, Oh MD, Choe KW. 2005. Bloodstream infections
 caused by antibiotic-resistant gram-negative bacilli: risk factors for mortality and impact of
 inappropriate initial antimicrobial therapy on outcome. Antimicrob Agents Chemother 49:760-766.

3603.Pitout JD, Laupland KB. 2008. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an361emerging public-health concern. Lancet Infect Dis 8:159-166.

3624.Biswas S, Brunel JM, Dubus JC, Reynaud-Gaubert M, Rolain JM. 2012. Colistin: an update on the363antibiotic of the 21st century. Expert Rev Anti Infect 10:917-934.

- Nordmann P, Poirel L, Toleman MA, Walsh TR. 2011. Does broad-spectrum beta-lactam resistance
 due to NDM-1 herald the end of the antibiotic era for treatment of infections caused by Gramnegative bacteria? J Antimicrob Chemoth 66:689-692.
- Gwynn MN, Portnoy A, Rittenhouse SF, Payne DJ. 2010. Challenges of antibacterial discovery revisited. Ann NY Acad Sci 1213:5-19.
- Coates AR, Halls G, Hu Y. 2011. Novel classes of antibiotics or more of the same? Brit J Pharmacol
 163:184-194.
- 3718.Thomson CJ, Power E, Ruebsamen-Waigmann H, Labischinski H. 2004. Antibacterial research and372development in the 21(st) Century--an industry perspective of the challenges. Curr Opin Microbiol3737:445-450.
- Livermore DM, British Society for Antimicrobial Chemotherapy Working Party on The Urgent Need:
 Regenerating Antibacterial Drug D, Development. 2011. Discovery research: the scientific challenge
 of finding new antibiotics. J Antimicrob Chemoth 66:1941-1944.
- Kalan L, Wright GD. 2011. Antibiotic adjuvants: multicomponent anti-infective strategies. Expert Rev Mol Med 13:e5.
- Hu Y, Liu A, Vaudrey J, Vaiciunaite B, Moigboi C, McTavish SM, Kearns A, Coates A. 2015.
 Combinations of beta-Lactam or Aminoglycoside Antibiotics with Plectasin Are Synergistic against Methicillin-Sensitive and Methicillin-Resistant *Staphylococcus aureus*. PLoS ONE 10:e0117664.

382	12.	Soothill G, Hu Y, Coates A. 2013. Can we prevent antimicrobial resistance by using antimicrobials
383		better? Pathogens 2: 422-435.
384	13.	Nielsen SB, Otzen DE. 2010. Impact of the antimicrobial peptide Novicidin on membrane structure
385		and integrity. J Colloid Interf Sci 345: 248-256.
386	14.	Dorosz J, Gofman Y, Kolusheva S, Otzen D, Ben-Tal N, Nielsen NC, Jelinek R. 2010. Membrane
387		interactions of novicidin, a novel antimicrobial peptide: phosphatidylglycerol promotes bilayer
388		insertion. J Phys Chem B 114 :11053-11060.
389	15.	Balakrishnan VS, Vad BS, Otzen DE. 2013. Novicidin's membrane permeabilizing activity is driven by
390		membrane partitioning but not by helicity: a biophysical study of the impact of lipid charge and
391		cholesterol. Biochim Biophys Acta 1834:996-1002.
392	16.	Odds FC. 2003. Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob
393		Chemoth 52:1.
394	17.	White RL, Burgess DS, Manduru M, Bosso JA. 1996. Comparison of three different in vitro methods of
395		detecting synergy: time-kill, checkerboard, and E test. Antimicrob Agents Chemother 40 :1914-1918.
396	18.	Hu Y, Coates AR. 2012. Enhancement by novel anti-methicillin-resistant <i>Staphylococcus aureus</i>
397	10.	compound HT61 of the activity of neomycin, gentamicin, mupirocin and chlorhexidine: in vitro and in
398		vivo studies. J Antimicrob Chemoth. 68 :374-84.
399	19.	Wu M, Hancock RE. 1999. Interaction of the cyclic antimicrobial cationic peptide bactenecin with the
400	19.	outer and cytoplasmic membrane. J Biol Chem 274 :29-35.
400	20	Spivey JM. 1992. The postantibiotic effect. Clin Pharm 11: 865-875.
	20.	
402	21.	Rodriguez-Pardo D, Pigrau C, Corona PS, Almirante B. 2015. An update on surgical and antimicrobial
403		therapy for acute periprosthetic joint infection: new challenges for the present and the future. Expert
404		Rev Anti-Infe 13: 249-265.
405	22.	Nastro M, Rodriguez CH, Monge R, Zintgraff J, Neira L, Rebollo M, Vay C, Famiglietti A. 2014. Activity
406		of the colistin-rifampicin combination against colistin-resistant, carbapenemase-producing Gram-
407		negative bacteria. J Chemother 26 :211-216.
408	23.	Drapeau CM, Grilli E, Petrosillo N. 2010. Rifampicin combined regimens for gram-negative infections:
409		data from the literature. Int J Antimicrob Ag 35: 39-44.
410	24.	Patel IH, Chen S, Parsonnet M, Hackman MR, Brooks MA, Konikoff J, Kaplan SA. 1981.
411		Pharmacokinetics of ceftriaxone in humans. Antimicrob Agents Chemother 20: 634-641.
412	25.	Leeder JS, Spino M, Tesoro AM, MacLeod SM. 1983. High-pressure liquid chromatographic analysis of
413		ceftazidime in serum and urine. J Antimicrob Chemoth 24: 720-724.
414	26.	Burgess DS. 2005. Use of pharmacokinetics and pharmacodynamics to optimize antimicrobial
415		treatment of <i>Pseudomonas aeruginosa</i> infections. Clin Infect Dis 40 Suppl 2: S99-104.
416	27.	Giacometti A, Cirioni O, Del Prete MS, Barchiesi F, Fortuna M, Drenaggi D, Scalise G. 2000. In vitro
417		activities of membrane-active peptides alone and in combination with clinically used antimicrobial
418		agents against Stenotrophomonas maltophilia. Antimicrob Agents Chemother 44:1716-1719.
419	28.	Anantharaman A, Rizvi MS, Sahal D. 2010. Synergy with rifampin and kanamycin enhances potency,
420		kill kinetics, and selectivity of de novo-designed antimicrobial peptides. Antimicrob Agents Chemother
421		54: 1693-1699.
422	29.	Bertelsen K, Dorosz J, Hansen SK, Nielsen NC, Vosegaard T. 2012. Mechanisms of peptide-induced
423		pore formation in lipid bilayers investigated by oriented 31P solid-state NMR spectroscopy. PLoS ONE
424		7 :e47745.
425	30.	Pages JM, Sandrine AF, Mahamoud A, Bolla JM, Davin-Regli A, Chevalier J, Garnotel E. 2010. Efflux
426		pumps of gram-negative bacteria, a new target for new molecules. Curr Top Med Chem 10:1848-
427		1857.
428	31.	Zechini B, Versace I. 2009. Inhibitors of multidrug resistant efflux systems in bacteria. Recent Pat Anti
429		infect Drug Discov 4: 37-50.
430	32.	Barbas JA, Diaz J, Rodriguez-Tebar A, Vazquez D. 1986. Specific location of penicillin-binding proteins
431		within the cell envelope of <i>Escherichia coli</i> . J Bacteriol 165: 269-275.
-J1		

Soothill G, Hu Y, Coates A. 2013. Can we prevent antimicrobial resistance by using antimicrobials

382

12.

432	33.	Kosowska-Shick K, McGhee PL, Appelbaum PC. 2010. Affinity of ceftaroline and other beta-lactams
433 434		for penicillin-binding proteins from <i>Staphylococcus aureus</i> and <i>Streptococcus pneumoniae</i> . Antimicrob Agents Chemother 54 :1670-1677.
435		

436

437

AAC

Accepted Manuscript Posted Online

	MIC range (mg/L)	MIC50 (mg/L)	MIC90 (mg/L)
Novicidin	1 - 8	2	4
Rifampicin	4 - >1024	16	32
Ceftriaxone	0.03125 - >2048	1024	2048
Cefixime	0.03125 - >2048	256	2048
Ceftazidime	0.03125 - >2048	128	1024
Cefotaxime	0.03125 - >2048	512	2048

Table 1. MIC values for novicidin and antibiotics used in this study.

			Total no. (%) of strains with activity when novicidin combined with		
Strains	Combination Activity	FICI	Rifampicin	Ceftriaxone	Ceftazidime
E. coli	Synergy	≤0.5	43 (70.5%)	35 (57.4%)	39 (63.9%)
	Indifferent	>0.5 <4	18 (29.5%)	26 (42.6%)	22 (36.1%)
	Antagonism	≥4	0	0	0
Isolates in KES group	Synergy	≤0.5	28 (84.8%)	23 (69.7%)	26 (78.8%)
	Indifferent	>0.5 <4	5 (15.2%)	10 (30.3%)	7 (21.2%)
	Antagonism	≥4	0	0	0
NDM-1 strains	Synergy	≤0.5	7 (100%)	-	-
	Indifferent	>0.5 <4	0	-	-
	Antagonism	≥4	0	-	-


Table 2. Combination activity of novicidin with rifampicin, ceftriaxone and ceftazidime
against the 101 Gram-negative Enterobacteriaceae strains

	•) of strains with activity with ceftriaxone and c	
Strains (total no.)	Synergy	Indifferent	Antagonism
	FICI ≤0.5	FICI >0.5 <4	FICI ≥4
Ceftriaxone resistant strains [58]	52 (89.7%)	6 (10.3%)	0
Ceftriaxone sensitive strains [36]	6 (16.7%)	30 (83.3%)	0
Ceftazidime resistant strains [68]	64 (94.1%)	4 (5.9%)	0
Ceftazidime sensitive strains [26]	1 (3.8%)	25 (96.2%)	0

Table 3. Combination activity of novicidin with ceftriaxone and ceftazidime against the 94 Gramnegative clinical isolates


_





1	FIG 1 Time-kill analysis showing the effects of novicidin in combination with rifampicin,
2	ceftriaxone and ceftazidime against antibiotic resistant E. coli and strains. The peptide and
3	antibiotics alone or each combined with novicidin were added to the bacterial cultures and
4	CFU counts were carried out at different time points. Combination of rifampicin at 2 mg/L
5	and novicidin at 1 mg/L (A) or 0.5 mg/L (B) against a clinical isolate of <i>E. coli</i> . Combination
6	of rifampicin at 256 mg/L and novicidin at 4 mg/L (C) or 2 mg/L (D) against a NDM-1 E.
7	coli. Combination of ceftriaxone at 2048 mg/L and novicidin at 1 mg/L (E) or 0.5 mg/L (F)
8	against a clinical isolate of E. coli. Combination of ceftriaxone at 2048 mg/L and novicidin at
9	2 mg/L (G) or 1 mg/L (H) against a clinical isolate of the KES group. Negative controls
10	were included as (I) combination of plectasin at 32 mg/L with rifampicin at 256 mg/L against
11	a DNM-1 E. coli and (J) combination of plectasin at 32 mg/L with ceftriaxone at 2048 mg/L
12	against a clinical isolate of the KES group. These results shown are mean with standard
13	deviation (SD) of two independent experiments.






Antimicrobial Agents and Chemotherapy FIG 2 Determination of cytoplasmic membrane potential by novicidin against a clinical isolate of *E. coli*. Log phase *E. coli* culture was incubated with DiSC3(5) to a final concentration of 0.4 μ M until no more quenching was detected, which was followed by addition of 0.1 M KCl. Novicidin were incubated with the cultures at different concentrations. The changes in fluorescence were monitored at various time points. The data was mean with SD of two independent experiments.

7

AAC

Antimicrobial Agents and Chemotherapy






FIG 3 Induction of PAE of rifampicin (A) and ceftriaxone (B) by novicidin against a clinical
isolate of *E. coli*. Concentrations used for single drug PAE induction are rifampicin 80 mg/L,
novicidin 2 mg/L and ceftriaxone 1024 mg/L. For combination PAE induction, rifampicin
was 20 mg/L and novicidin was 0.625 mg/L; ceftriaxone was 640 mg/L and novicidin was
0.625 mg/L. The data was mean with SD of two independent experiments.

6

Novicidin concentration (mg/L)	Haemolysis (%)
125	4.4
250	7.7
500	13.2
750	13.3
1000	19.9
Negative control*	0
Positive control**	100

*blood was mixed with saline solution. **blood was mixed with distilled water

	Concentrations (mg/L)	Viability (%)		
		24 hours	72 hours	
Novicidin	0	100	100	
	25	95	102	
	50	93	102	
	100	99	98	
	200	99	101	
SDS	80	80	55	
	100	9	0	
	120	0	0	